Is Abivax SA Stock a Good Investment?
Abivax SA Investment Advice | ABVX |
- Examine Abivax SA's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Abivax SA's leadership team and their track record. Good management can help Abivax SA navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Abivax SA's business and its evolving consumer preferences.
- Compare Abivax SA's performance and market position to its competitors. Analyze how Abivax SA is positioned in terms of product offerings, innovation, and market share.
- Check if Abivax SA pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Abivax SA's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Abivax SA American stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Abivax SA American is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Abivax SA Stock
Researching Abivax SA's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 45.0% of the company shares are held by institutions such as insurance companies. The book value of Abivax SA was presently reported as 2.01. The company recorded a loss per share of 3.66. Abivax SA American had not issued any dividends in recent years.
To determine if Abivax SA is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Abivax SA's research are outlined below:
| Abivax SA American had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 4.62 M. Net Loss for the year was (147.74 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Abivax SA generates negative cash flow from operations | |
| Latest headline from thelincolnianonline.com: ABIVAX Socit Anonyme Given Equal Weight Rating at Morgan Stanley |
Abivax SA Quarterly Good Will |
|
Abivax SA's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 649.94 M.Market Cap |
|
Abivax SA's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.56) | (0.59) | |
| Return On Capital Employed | (0.57) | (0.60) | |
| Return On Assets | (0.52) | (0.55) | |
| Return On Equity | (0.87) | (0.91) |
Determining Abivax SA's profitability involves analyzing its financial statements and using various financial metrics to determine if Abivax SA is a good buy. For example, gross profit margin measures Abivax SA's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Abivax SA's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Abivax SA's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Abivax SA American. Check Abivax SA's Beneish M Score to see the likelihood of Abivax SA's management manipulating its earnings.
Evaluate Abivax SA's management efficiency
Abivax SA American has return on total asset (ROA) of (0.4669) % which means that it has lost $0.4669 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7146) %, meaning that it created substantial loss on money invested by shareholders. Abivax SA's management efficiency ratios could be used to measure how well Abivax SA manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.59 in 2025. Return On Capital Employed is likely to drop to -0.6 in 2025. At this time, Abivax SA's Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 4.3 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 36.6 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 5.23 | 4.97 | |
| Tangible Book Value Per Share | 4.57 | 4.34 | |
| Enterprise Value Over EBITDA | (1.95) | (2.05) | |
| Price Book Value Ratio | 1.94 | 1.84 | |
| Enterprise Value Multiple | (1.95) | (2.05) | |
| Price Fair Value | 1.94 | 1.84 | |
| Enterprise Value | 203.8 M | 181.3 M |
The leadership approach at Abivax SA's fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Beta 1.423 |
Basic technical analysis of Abivax Stock
As of the 24th of March, Abivax SA shows the Downside Deviation of 4.67, mean deviation of 3.05, and Risk Adjusted Performance of 0.0393. Abivax SA American technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Understand Abivax SA's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Abivax SA's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0393 | |||
| Market Risk Adjusted Performance | 0.1774 | |||
| Mean Deviation | 3.05 | |||
| Semi Deviation | 4.5 | |||
| Downside Deviation | 4.67 | |||
| Coefficient Of Variation | 2838.36 | |||
| Standard Deviation | 4.51 | |||
| Variance | 20.36 | |||
| Information Ratio | 0.0479 | |||
| Jensen Alpha | 0.2089 | |||
| Total Risk Alpha | 0.4917 | |||
| Sortino Ratio | 0.0464 | |||
| Treynor Ratio | 0.1674 | |||
| Maximum Drawdown | 29.82 | |||
| Value At Risk | (6.03) | |||
| Potential Upside | 6.04 | |||
| Downside Variance | 21.77 | |||
| Semi Variance | 20.28 | |||
| Expected Short fall | (3.21) | |||
| Skewness | (0.56) | |||
| Kurtosis | 4.71 |
| Risk Adjusted Performance | 0.0393 | |||
| Market Risk Adjusted Performance | 0.1774 | |||
| Mean Deviation | 3.05 | |||
| Semi Deviation | 4.5 | |||
| Downside Deviation | 4.67 | |||
| Coefficient Of Variation | 2838.36 | |||
| Standard Deviation | 4.51 | |||
| Variance | 20.36 | |||
| Information Ratio | 0.0479 | |||
| Jensen Alpha | 0.2089 | |||
| Total Risk Alpha | 0.4917 | |||
| Sortino Ratio | 0.0464 | |||
| Treynor Ratio | 0.1674 | |||
| Maximum Drawdown | 29.82 | |||
| Value At Risk | (6.03) | |||
| Potential Upside | 6.04 | |||
| Downside Variance | 21.77 | |||
| Semi Variance | 20.28 | |||
| Expected Short fall | (3.21) | |||
| Skewness | (0.56) | |||
| Kurtosis | 4.71 |
Consider Abivax SA's intraday indicators
Abivax SA intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Abivax SA stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Abivax SA Corporate Filings
6K | 24th of March 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
| 19th of November 2024 Other Reports | ViewVerify | |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Abivax Stock media impact
Far too much social signal, news, headlines, and media speculation about Abivax SA that are available to investors today. That information is available publicly through Abivax media outlets and privately through word of mouth or via Abivax internal channels. However, regardless of the origin, that massive amount of Abivax data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Abivax SA news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Abivax SA relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Abivax SA's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Abivax SA alpha.
Abivax SA Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Abivax SA can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Abivax SA Corporate Management
| Chris Rabbat | VP Affairs | Profile | |
| Ana MPH | VP Quality | Profile | |
| MBA BS | Chief Officer | Profile | |
| Jrme Denis | Executive Manufacturing | Profile | |
| Patrick Malloy | Senior Relations | Profile | |
| Didier Scherrer | Chief Officer | Profile |
Already Invested in Abivax SA American?
The danger of trading Abivax SA American is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Abivax SA is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Abivax SA. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Abivax SA American is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Abivax Stock Analysis
When running Abivax SA's price analysis, check to measure Abivax SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abivax SA is operating at the current time. Most of Abivax SA's value examination focuses on studying past and present price action to predict the probability of Abivax SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abivax SA's price. Additionally, you may evaluate how the addition of Abivax SA to your portfolios can decrease your overall portfolio volatility.